Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin T, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Cohen AD, et al. Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526. Blood. 2023. PMID: 36095849 Free PMC article.
Origin of Waldenstrom's macroglobulinaemia.
García-Sanz R, Jiménez C, Puig N, Paiva B, Gutiérrez NC, Rodríguez-Otero P, Almeida J, San Miguel J, Orfão A, González M, Pérez-Andrés M. García-Sanz R, et al. Best Pract Res Clin Haematol. 2016 Jun;29(2):136-147. doi: 10.1016/j.beha.2016.08.024. Epub 2016 Oct 6. Best Pract Res Clin Haematol. 2016. PMID: 27825459 Review.
Is immunotherapy here to stay in multiple myeloma?
Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Rodríguez-Otero P, et al. Haematologica. 2017 Mar;102(3):423-432. doi: 10.3324/haematol.2016.152504. Epub 2017 Jan 12. Haematologica. 2017. PMID: 28082344 Free PMC article. Review.
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.
Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF. Rodríguez-Otero P, et al. Leukemia. 2018 Nov;32(11):2427-2434. doi: 10.1038/s41375-018-0072-6. Epub 2018 Feb 23. Leukemia. 2018. PMID: 29515235
Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
Sanoja-Flores L, Flores-Montero J, Garcés JJ, Paiva B, Puig N, García-Mateo A, García-Sánchez O, Corral-Mateos A, Burgos L, Blanco E, Hernández-Martín J, Pontes R, Díez-Campelo M, Millacoy P, Rodríguez-Otero P, Prosper F, Merino J, Vidriales MB, García-Sanz R, Romero A, Palomera L, Ríos-Tamayo R, Pérez-Andrés M, Blanco JF, González M, van Dongen JJM, Durie B, Mateos MV, San-Miguel J, Orfao A; EuroFlow consortium. Sanoja-Flores L, et al. Blood Cancer J. 2018 Nov 19;8(12):117. doi: 10.1038/s41408-018-0153-9. Blood Cancer J. 2018. PMID: 30455467 Free PMC article.
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Moreno L, Perez C, Zabaleta A, Manrique I, Alignani D, Ajona D, Blanco L, Lasa M, Maiso P, Rodriguez I, Garate S, Jelinek T, Segura V, Moreno C, Merino J, Rodriguez-Otero P, Panizo C, Prosper F, San-Miguel JF, Paiva B. Moreno L, et al. Clin Cancer Res. 2019 May 15;25(10):3176-3187. doi: 10.1158/1078-0432.CCR-18-1597. Epub 2019 Jan 28. Clin Cancer Res. 2019. PMID: 30692097
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature.
Rodríguez-Otero P, Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Nuñez-Córdoba JM, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Puig N, Oriol A, Paiva B, Bladé J, Lahuerta JJ, San Miguel JF. Rodríguez-Otero P, et al. Blood Cancer J. 2019 Mar 18;9(4):36. doi: 10.1038/s41408-019-0176-x. Blood Cancer J. 2019. PMID: 30886139 Free PMC article.
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.
Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J. Mateos MV, et al. Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. Br J Haematol. 2019. PMID: 31090915 Free article. Clinical Trial. No abstract available.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. Chari A, et al. Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21. Blood. 2019. PMID: 31113777 Free PMC article. Clinical Trial.
101 results